• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
Selected Journal Articles for the Week of January 18th

Selected Journal Articles for the Week of January 18th

by MM360 Staff | Jan 19, 2021 | Featured News, Myeloma News

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice Background: We have performed a head to head comparison of all-oral triplet...
Delaying Daratumumab until Second Line in Transplant-ineligible Patients More Cost Effective

Delaying Daratumumab until Second Line in Transplant-ineligible Patients More Cost Effective

by MM360 Staff | Jan 12, 2021 | Featured News, Myeloma News

A study published in the Journal of Clinical Oncology suggests that using daratumumab in the first-line setting for transplant-ineligible patients may not be cost-effective under current pricing. the cost of daratumumab would need to be decreased by 67% for first-line...
Melflufen Plus Dexamethasone in RRMM Shows Durable Response

Melflufen Plus Dexamethasone in RRMM Shows Durable Response

by MM360 Staff | Jan 12, 2021 | Featured News, Myeloma News

Updated survival data for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy was published in the British Journal of Haematology. The...
Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study

Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study

by MM360 Staff | Dec 21, 2020 | Featured News, Myeloma News

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab...
FDA Approval of Selinexor After At Least One Prior Therapy

FDA Approval of Selinexor After At Least One Prior Therapy

by MM360 Staff | Dec 18, 2020 | Featured News, Myeloma News

The U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor) an oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at...
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT